Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia
Public ClinicalTrials.gov record NCT02813694. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Oral Lefamulin (BC 3781) Versus Oral Moxifloxacin in Adults With Community-Acquired Bacterial Pneumonia
Study identification
- NCT ID
- NCT02813694
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Nabriva Therapeutics AG
- Industry
- Enrollment
- 738 participants
Conditions and interventions
Conditions
Interventions
- lefamulin Drug
- Moxifloxacin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2016
- Primary completion
- Dec 31, 2017
- Completion
- Dec 31, 2017
- Last update posted
- Oct 22, 2019
2016 – 2018
United States locations
- U.S. sites
- 25
- U.S. states
- 13
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1080 | Beverly Hills | California | — | — |
| Site 1065 | Fresno | California | 93701 | — |
| 1078 | Northridge | California | — | — |
| Site 1072 | Oxnard | California | 93030 | — |
| Site 1070 | Sacramento | California | 95817 | — |
| 1079 | Sherman Oaks | California | — | — |
| Site 1053 | Sylmar | California | 91342 | — |
| Site 1064 | DeBary | Florida | 32713 | — |
| Site 1052 | DeLand | Florida | 32720 | — |
| 1076 | Miami | Florida | — | — |
| Site 1051 | Michigan City | Indiana | 46360 | — |
| Site 1057 | Natchitoches | Louisiana | 71457 | — |
| Site 1073 | New Bedford | Massachusetts | 02740 | — |
| Site 1055 | Detroit | Michigan | 48201 | — |
| Site 1062 | Detroit | Michigan | 48235 | — |
| Site 1068 | Royal Oak | Michigan | 48073 | — |
| Site 1058 | St Louis | Missouri | 63110 | — |
| Site 1054 | Butte | Montana | 59701 | — |
| Site 1067 | Lima | Ohio | 45801 | — |
| Site 1056 | Rapid City | South Dakota | 57702 | — |
| 1077 | Hendersonville | Tennessee | — | — |
| Site 1060 | Houston | Texas | 77070 | — |
| Site 1069 | Houston | Texas | 77093 | — |
| Site 1066 | Splendora | Texas | 77372 | — |
| Site 1059 | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 130 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02813694, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 22, 2019 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02813694 live on ClinicalTrials.gov.